CEBPA and neoplasm: Immunohistochemistry (IHC) staining of the two tumor samples demonstrated CEBPA protein in the nucleus of tumor cells from the Cisplatin-sensitive patient, but not in those from the Cisplatin-resistant patient; further, TRIB2 protein was detectable in the cytoplasm and nucleus of tumor cells from the Cisplatin-resistant patient, but not in those from the Cisplatin-sensitive patient (Figure 6C-6F).